Pemetrexed & Malignant neoplasm progression

4.4%

of users reported Malignant neoplasm progression

78.5%

also reported Severe reaction

52.7%

are men

Severe reaction

78.5%

Hospitalization

12.9%

Death

7.5%

Life-threatening condition

1.1%

Pemetrexed: general information

30 - 39 years

0.5%

40 - 49 years

7.8%

50 - 59 years

22.9%

60 - 69 years

37.9%

70 - 79 years

27.7%

80 - 89 years

3.2%